tirzepatide cardiovascular trial for Heart Failure in Patients with Obesity Tirzepatide shows cardiovascular safety in

Ozempic and Victoza work the same way, but they have some differences

Lipohypertrophy develops at the overused site, drug absorption becomes unpredictable, and your carefully optimized timing becomes meaningless because the pharmacokinetics are no longer reliable

Pacing and rest are also important

Other than that, users have experienced different changes in their energy and libido levels

In March 2026, Structure reported 44-week topline data from the ACCESS II Phase 2 study, showing placebo-adjusted weight loss of up to 16.3%, which the company described as the highest efficacy demonstrated among oral GLP-1 receptor agonists at that time point